# Control of Lipogenesis and Hepatic Steatosis by Caspase-2

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $546,309

## Abstract

Project Summary
We have established the existence of an endoplasmic reticulum (ER) stress responsive and caspase 2
(Casp2) dependent pathway that leads to activation of sterol regulatory element binding proteins 1 and 2
(SREBP1/2), the master regulators of fatty acid and cholesterol metabolism. The Casp2-dependent
pathway operates independently of SREBP cleavage activation protein (SCAP), the major activator of
canonical SREBP signaling and the target for its feedback inhibition and negative regulation by sterols and
other lipids. SCAP-dependent SREBP signaling is activated when sterol concentrations are low and during
hepatic insulin resistance and may account for simple steatosis (NAFL), the benign form of non-alcoholic
fatty liver disease (NAFLD). Conversely, the Casp2-dependent pathway is activated during hepatocyte ER
stress and leads to non-alcoholic steatohepatitis (NASH), the aggressive form of NAFLD, characterized by
liver damage and inflammation, and at advanced stages by loss of liver fat. Importantly, we discovered
that the two pathways are engaged in negative crosstalk, such that SCAP-dependent SREBP activation
attenuates ER stress, likely via ER membrane expansion, whereas activation of the Casp2-dependent
pathway by the ER stress sensor and transducer IRE1 is associated with induction of INSIG2, an inhibitor
of SCAP-dependent SREBP activation. Moreover, inhibition of SCAP-dependent SREBP signaling
potentiates ER stress, which enhances IRE1 activation, resulting in elevated expression of INSIG2, Casp2
and PIDD1, a component of the PIDDosome complex, which includes Casp2 and the scaffold protein
RAIDD. In addition to Casp2 activation, PIDD1 may target the PIDDosome complex to the ER membrane,
thereby enabling cleavage of site 1 protease (S1P) by Casp2, the first step in the non-canonical SREBP
activation pathway. We postulate that the mutually exclusive interactions between the two pathways
contribute to the sharp transition from simple steatosis to NASH. We will test this hypothesis in three
specific aims. 1. Test the hypothesis that elevated IRE1 activity, Casp2 activation and inhibition of SCAP-
dependent SREBP activation control human NASH progression, using an extensive collection of NAFLD
biopsies available at UCSD and a novel human liver spheroid model of NAFLD/NASH. 2. Test the
hypothesis that INSIG2 induction inhibits SCAP-dependent SREBP activation and potentiates the Casp2-
dependent pathway by enhancing ER stress and IRE1 activation. These studies will be conducted in
mouse models and will deploy state-of-the-art high-content spatial transcriptomics. 3. Determine the role
of IRE1 and its downstream effectors in NAFL to NASH progression in mouse models and human
spheroids, and the suitability of these mediators to therapeutic targeting. Impact: these studies will shed
new light on the mechanistic basis for Casp2-dependent SREBP activation and the role of ER stress, IRE1
and its effectors in NASH pathogenesis, laying the fo...

## Key facts

- **NIH application ID:** 10735256
- **Project number:** 2R01DK120714-05A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Michael Karin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $546,309
- **Award type:** 2
- **Project period:** 2019-03-15 → 2027-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10735256

## Citation

> US National Institutes of Health, RePORTER application 10735256, Control of Lipogenesis and Hepatic Steatosis by Caspase-2 (2R01DK120714-05A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10735256. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*